Biological Dynamics (BD), a leading medtech company, is streamlining its operations by separating its diagnostic and biosciences businesses from the rest of the company. The move aims to position BD as a pure-play medtech leader, focusing on medical essentials, interventional devices, and pharmaceutical systems.
The new “New BD” will retain its hardware for collecting blood samples and delivering IV medications, as well as its interventional devices and connected care programs. The pharmaceutical systems unit will be renamed biopharma systems, with a focus on developing delivery devices for drugs and biologics.
The outgoing diagnostic solutions and biosciences business is expected to deliver substantial value as a pure-play leader in life sciences. This division generated $3.4 billion in 2024 sales and includes tests for infectious disease and cervical cancer screening, as well as flow cytometry instruments and single-cell multiomics tools used in research.
BD’s board of directors has approved the transaction, which is expected to support the company’s plans for more tuck-in acquisitions. The move follows a five-year strategy called BD 2025, which aims for long-term revenue growth of 5.5% or more in high-growth and high-margin markets.
The separation is expected to be completed by the end of the year, with more specifics to be announced by the close of 2025 fiscal calendar. The company reported its first-quarter earnings results for fiscal 2025, with revenues of $5.17 billion, representing a 9.8% gain or 3.9% organic growth.
Source: https://www.fiercebiotech.com/medtech/bd-bids-farewell-its-diagnostic-bioscience-divisions-company-split